The Centers for Disease Control and Prevention recently reported 81,000 overdose deaths in the 12 months ending May 2020. This figure represents the highest number of overdose deaths ever recorded during a 12-month period. The CDC data also showed that overdose deaths involving cocaine and psychostimulants (methamphetamine) increased 26.5% and 34.8%, respectively â meaning the number of overdose deaths involving psychostimulants now outnumber cocaine-related deaths.
Unlike opioid use disorder, which has evidence-based medications with demonstrated mortality benefits, methamphetamine use disorder is harder to treat. While there are patient-centered strategies aimed at engaging patients who use methamphetamines in treatment â which includes cognitive-behavioral therapy and contingency management â there remains a lack of medications aimed at counteracting the effect or reducing the use of methamphetamines.
There may be some hope. A new study in the New England Journal of Medicine demonstrates that 14% of patients who used methamphetamines and were prescribed a combination of naltrexone, which blocks opioid receptors, and bupropion, an antidepressant, had improvement in their substance use as demonstrated by reduction of urine toxicology screens positive for methamphetamines. This is a modest rate but it represents an amount 5 times more than trial participants who received the placebo.
Why this potential methamphetamine addiction treatment is a game-changer
Justin Alves, MSN, RN, ACRN, CARN, CNE a nurse educator at Boston Medical Centerâs Office-Based Addiction Treatment (OBAT), weighs in on the findings.